Terms: = Endocrine gland cancer AND SERPINE1, PAI, PAI-1, PAI1, PLANH1 AND Prognosis
41 results:
1. High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinoma.
Zhu Y; Zheng D; Lei L; Cai K; Xie H; Zheng J; Yu C
BMC Cancer; 2022 Oct; 22(1):1042. PubMed ID: 36199068
[TBL] [Abstract] [Full Text] [Related]
2. Liver-Metastasis-Related Genes are Potential Biomarkers for Predicting the Clinical Outcomes of Patients with Pancreatic Adenocarcinoma.
Dong Y; Tian J; Yan B; Lv K; Li J; Fu D
Pathol Oncol Res; 2021; 27():1609822. PubMed ID: 34290570
[TBL] [Abstract] [Full Text] [Related]
3. Using The cancer Genome Atlas data to refine the 8th edition of the American Joint Committee on cancer staging for papillary thyroid carcinoma.
Poma AM; Macerola E; Torregrossa L; Elisei R; Santini F; Basolo F
Endocrine; 2021 Apr; 72(1):140-146. PubMed ID: 32915437
[TBL] [Abstract] [Full Text] [Related]
4. Pancreatic stellate cells activated by mutant KRAS-mediated pai-1 upregulation foster pancreatic cancer progression via IL-8.
Wang HC; Lin YL; Hsu CC; Chao YJ; Hou YC; Chiu TJ; Huang PH; Tang MJ; Chen LT; Shan YS
Theranostics; 2019; 9(24):7168-7183. PubMed ID: 31695760
[No Abstract] [Full Text] [Related]
5. TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
Melisi D; Garcia-Carbonero R; Macarulla T; Pezet D; Deplanque G; Fuchs M; Trojan J; Kozloff M; Simionato F; Cleverly A; Smith C; Wang S; Man M; Driscoll KE; Estrem ST; Lahn MMF; Benhadji KA; Tabernero J
Cancer Chemother Pharmacol; 2019 May; 83(5):975-991. PubMed ID: 30887178
[TBL] [Abstract] [Full Text] [Related]
6. Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma.
Liu WJ; Zhou L; Liang ZY; Zhou WX; You L; Zhang TP; Zhao YP
Chin Med J (Engl); 2018 Dec; 131(24):2947-2952. PubMed ID: 30539907
[TBL] [Abstract] [Full Text] [Related]
7. pai-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination.
Peng Y; Kajiyama H; Yuan H; Nakamura K; Yoshihara M; Yokoi A; Fujikake K; Yasui H; Yoshikawa N; Suzuki S; Senga T; Shibata K; Kikkawa F
Cancer Lett; 2019 Feb; 442():181-192. PubMed ID: 30429105
[TBL] [Abstract] [Full Text] [Related]
8. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
Mashiko S; Kitatani K; Toyoshima M; Ichimura A; Dan T; Usui T; Ishibashi M; Shigeta S; Nagase S; Miyata T; Yaegashi N
Cancer Biol Ther; 2015; 16(2):253-60. PubMed ID: 25587663
[TBL] [Abstract] [Full Text] [Related]
9. Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.
Chen S; Tai H; Tong X; Wang J; Yang F; Yang Y; Yiqin O
J Obstet Gynaecol Res; 2014 Sep; 40(9):2058-65. PubMed ID: 25181626
[TBL] [Abstract] [Full Text] [Related]
10. Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study.
Battista MJ; Mantai N; Sicking I; Cotarelo C; Weyer V; Lebrecht A; Solbach C; Schmidt M
Oncol Rep; 2014 May; 31(5):2213-9. PubMed ID: 24627004
[TBL] [Abstract] [Full Text] [Related]
11. VEGF and Id-1 in pancreatic adenocarcinoma: prognostic significance and impact on angiogenesis.
Georgiadou D; Sergentanis TN; Sakellariou S; Filippakis GM; Zagouri F; Vlachodimitropoulos D; Psaltopoulou T; Lazaris AC; Patsouris E; Zografos GC
Eur J Surg Oncol; 2014 Oct; 40(10):1331-7. PubMed ID: 24480377
[TBL] [Abstract] [Full Text] [Related]
12. [Clinical prospects of tumor-associated proteases and their tissue inhibitors investigation in oncologic patient].
Gershteĭn ES; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 2013; (5):16-27. PubMed ID: 24000664
[TBL] [Abstract] [Full Text] [Related]
13. Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance.
Ren F; Shi H; Zhang G; Zhang R
J Exp Clin Cancer Res; 2013 Aug; 32(1):60. PubMed ID: 23988121
[TBL] [Abstract] [Full Text] [Related]
14. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
Horvatic Herceg G; Herceg D; Kralik M; Kulic A; Bence-Zigman Z; Tomic-Brzac H; Bracic I; Kusacic-Kuna S; Prgomet D
Otolaryngol Head Neck Surg; 2013 Oct; 149(4):533-40. PubMed ID: 23835563
[TBL] [Abstract] [Full Text] [Related]
15. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract] [Full Text] [Related]
16. The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Baldini E; Sorrenti S; D'Armiento E; Di Matteo FM; Catania A; Ulisse S
G Chir; 2012 Oct; 33(10):305-10. PubMed ID: 23095556
[TBL] [Abstract] [Full Text] [Related]
17. Biological significance of plasminogen activator inhibitor-1 expression in ovarian clear cell adenocarcinoma.
Komiyama S; Aoki D; Saitoh E; Komiyama M; Udagawa Y
Eur J Gynaecol Oncol; 2011; 32(6):611-4. PubMed ID: 22335020
[TBL] [Abstract] [Full Text] [Related]
18. Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells.
Lupu-Meiri M; Geras-Raaka E; Lupu R; Shapira H; Sandbank J; Segal L; Gershengorn MC; Oron Y
J Cell Physiol; 2012 Nov; 227(11):3621-8. PubMed ID: 22331587
[TBL] [Abstract] [Full Text] [Related]
19. Ligand-dependent EGFR activation induces the co-expression of IL-6 and pai-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
[TBL] [Abstract] [Full Text] [Related]
20. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract] [Full Text] [Related]
[Next]
